GRB7 is required for triple-negative breast cancer cell invasion and survival

Orsi Giricz, Verónica Calvo, Stephanie C. Pero, David N. Krag, Joseph A. Sparano, Paraic A. Kenny

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Triple-negative breast cancer (TNBC) is a heterogeneous disease that is usually associated with poor prognosis, and frequently associated with the basal-like breast cancer gene expression profile. There are no targeted therapeutic modalities for this disease, and no useful bio-markers. High GRB7 RNA expression levels are associated with an elevated risk of recurrence in patients with operable TNBC treated with standard adjuvant anthracycline and taxane therapy. To determine whether GRB7 is involved in the pathobiology of TNBC, we evaluated the biological effects of GRB7 inhibition in a panel of triple-negative cell lines=MDA-MB-468, MDA-MB-231, HCC70, and T4-2. We found GRB7 inhibition reduced cell motility and invasion of these cell lines and promoted cell death by apoptosis in 3D culture. These data suggest that GRB7 itself, or GRB7-dependent pathways, may prove to be important therapeutic targets in this disease.

Original languageEnglish (US)
Pages (from-to)607-615
Number of pages9
JournalBreast Cancer Research and Treatment
Issue number2
StatePublished - Jun 2012


  • Adapter proteins
  • GRB7
  • Receptor tyrosine kinase signaling
  • Triple-negative breast cancer
  • Tumor cell invasion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'GRB7 is required for triple-negative breast cancer cell invasion and survival'. Together they form a unique fingerprint.

Cite this